Diagnosis and misdiagnosis of HHT

Hereditary Hemorrhagic Telangiectasia (HHT), also sometimes referred to as Osler-Weber-Rendu (OWR), is a genetic disorder of the blood vessels affecting approximately 1 in 5,000 people totaling 1.4 million worldwide. While HHT affects specific areas or organs of the body, it’s important to understand the potential impact on other aspects of life as well. To ensure the best possible health for you or your loved ones, remember to consider how HHT might impact or cause the following: aging, pregnancy, iron deficiency, genetic testing, anemia.

As HHT symptoms are often mistaken for other conditions, knowing the common misdiagnoses can lead to faster identification and significant improvements in quality of life.

## Affected Organs

HHT does not affect every individual in the same way. Some people may have symptoms in several different parts of the body, while some may show hardly any symptoms at all.

1. **BRAIN**

   - Up to 23% of people with HHT have arteriovenous malformations (AVM) in the brain, and in most cases can be successfully treated. If left untreated, brain AVMs can be disabling or deadly, and because they often have no symptoms prior to bleeding, HHT physicians in North America recommend brain screening for anyone diagnosed with HHT, even infants and during developmental growth periods until age 21.

   **Common Misdiagnosis:** Aneurism, Cerebral Hemorrhage, Epilepsy, Abscess, Migraine, Stroke

   **Treatment:** Embolization, Radiation, Surgical Removal

2. **LUNGS**

   - 40-50% of people with HHT have arteriovenous malformations (AVM) in the lungs. Those with HHT1 (Endoglin) are 5-10 times more likely to have pulmonary AVMs (PAVMs) than people with HHT2 (ACVRL1 or ALK1). PAVMs are at higher risk of rupturing when blood volume in the body increases (i.e. during pregnancy). Until PAVMs are excluded by testing, a person over the age of 10 with known or suspected HHT should take antibiotics before all dental work or medical procedures that could introduce bacteria to the blood stream.

   **Common Misdiagnosis:** Asthma, Alzheimer’s Disease, Lung Disease, Tumor, Stroke, Polycythemia, shortness of breath, coughing up blood, Infertility, Patent Foramen Ovale (PFO), Migraines, Brain Abscess, Stroke

   **Treatment:** Endovascular Embolization

3. **SPINE**

   - Spinal arteriovenous malformations (AVM) are rare, affecting only about 1% of HHT patients. They can cause back pain and sometimes lead to loss of feeling or mobility in an arm or leg. If untreated, spinal AVMs can lead to further motor or sensory deficit, aneurysm, and high blood pressure.

   **Common Misdiagnosis:** Scoliosis, Stroke

   **Treatment:** Endovascular Embolization, surgery, Radiation Therapy

CONTINUED ➔
95% of people with HHT have telangiectasias on the skin of the hands, face, and mouth, although they may not be visible until an individual is 30 or 40. Telangiectasias appear as tiny red or purple spots between the size of a pinpoint and pinhead. Rupture and bleeding of telangiectasias is common in the nose but less so in the mouth, face, or hands.

**Common Misdiagnosis:** Birthmarks, Cherry Angioma

**Treatment:** Laser

---

Arteriovenous malformations (AVM) occur in the liver of 32-75% of people with HHT, but it is estimated that only about 8% of those affected show symptoms. Untreated liver AVMs can lead to heart failure, typically in combination with aging when the heart has been overworked for years by pumping extra blood through the low-resistance pathway of the AVM.

**Common Misdiagnosis:** Cirrhosis, Heart Failure, shortness of breath

**Treatment:** Intravenous blood vessel inhibitor drugs, additional therapeutic management, transplant

---

80% of HHT patients have telangiectasias in the stomach or intestines, though it is estimated that only 20% ever develop obvious gastrointestinal bleeding. Bleeding can range from mild to severe and can occur anywhere in the GI system including the esophagus and large intestine. The most common sites are the stomach and upper portion of the small intestine.

**Common Misdiagnosis:** Black stool, Angiodysplasia, unexplained Anemia, Cancer

**Treatment:** Heater Probe, Bicap, Argon Photocoagulation, Laser, Intravenous blood vessel inhibitor drugs, Oral Medication

---

Recurring nosebleeds (Epistaxis) affect about 90% of people with HHT and are the most common symptom of the disease. Epistaxis is caused when telangiectasias in the nose rupture, leading to nosebleeds of varying severity, length, and frequency. Typically nosebleeds begin around age 12 but can appear as early as infancy or as late as adulthood. 10% of HHT patients will not have nose bleeds even though they may have ‘silent manifestations’ that could be potentially dangerous.

**Common Misdiagnosis:** Allergies, Drug Addiction, Hemophilia, Von Willebrand Disease

**Treatment:** Over the counter sprays/gels, moisture & humidification, Drug Therapy, Sclerotherapy, Surgery, Coblation

---

95% of people with HHT have telangiectasias on the skin of the hands, face, and mouth, although they may not be visible until an individual is 30 or 40. Telangiectasias appear as tiny red or purple spots between the size of a pinpoint and pinhead. Rupture and bleeding of telangiectasias is common in the nose but less so in the mouth, face, or hands.

**Common Misdiagnosis:** Birthmarks, Cherry Angioma

**Treatment:** Laser